{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:29:12Z","timestamp":1791822552484,"version":"4.3.4"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009104","name":"University of Modena and Reggio Emilia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP E93C22001860006"],"award-info":[{"award-number":["CUP E93C22001860006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119626","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:53:29Z","timestamp":1780826009000},"page":"119626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cancer-associated and non-neoplastic fibrosis: Comparative mechanisms and emerging antifibrotic strategies"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-3589","authenticated-orcid":false,"given":"Beatrice","family":"Ricc\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grisendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Lo","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilia","family":"Giuggioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Clini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7835","key":"10.1016\/j.biopha.2026.119626_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119626_bib3","article-title":"Decoding tumor-fibrosis interplay: mechanisms, impact on progression, and innovative therapeutic strategies","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Sig Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib5","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1038\/s41467-022-30633-9","article-title":"Identification, discrimination and heterogeneity of fibroblasts","volume":"13","author":"Lendahl","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119626_bib6","doi-asserted-by":"crossref","unstructured":"Maria A.T.J., Partouche L., Goulabchand R., Rivi\u00e8re S., Rozier P., Bourgier C., et al. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. Front Immunol. 9:3112. doi:10.3389\/fimmu.2018.03112.","DOI":"10.3389\/fimmu.2018.03112"},{"issue":"12","key":"10.1016\/j.biopha.2026.119626_bib7","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3390\/jpm12122007","article-title":"Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study","volume":"12","author":"Isca","year":"2022","journal-title":"J. Pers. Med."},{"issue":"02","key":"10.1016\/j.biopha.2026.119626_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0035-1550057","article-title":"Resolution of liver fibrosis: basic mechanisms and clinical relevance","volume":"35","author":"Ramachandran","year":"2015","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1164\/rccm.201508-1638OC","article-title":"Stretch-induced activation of transforming growth factor-\u03b2 1 in Pulmonary Fibrosis","volume":"194","author":"Froese","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119626_bib10","doi-asserted-by":"crossref","unstructured":"Chen F., Lyu L., Xing C., Chen Y., Hu S., Wang M., et al. The pivotal role of TGF-\u03b2\/Smad pathway in fibrosis pathogenesis and treatment. Front Oncol. 15:1649179. doi:10.3389\/fonc.2025.1649179.","DOI":"10.3389\/fonc.2025.1649179"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/biom13010119","article-title":"The Role of JAK\/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms","volume":"13","author":"Liu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119626_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.phrs.2016.04.010","article-title":"Notch in fibrosis and as a target of anti-fibrotic therapy","volume":"108","author":"Hu","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154719","article-title":"NF-\u03baB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model","volume":"8","author":"Sieber","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119626_bib15","doi-asserted-by":"crossref","unstructured":"Gu C., Shi X., Dang X., Chen J., Chen C., Chen Y., et al. Identification of Common Genes and Pathways in Eight Fibrosis Diseases. Front Genet. 11:627396. doi:10.3389\/fgene.2020.627396.","DOI":"10.3389\/fgene.2020.627396"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12931-024-02989-7","article-title":"SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K\/Akt\/mTOR pathway","volume":"25","author":"Yue","year":"2024","journal-title":"Respir. Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib17","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/s12276-025-01551-9","article-title":"The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer","volume":"57","author":"Kim","year":"2025","journal-title":"Exp. & Mol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/intbio\/zyab012","article-title":"Spatiotemporal model of cellular mechanotransduction via Rho and YAP","volume":"13","author":"Novev","year":"2021","journal-title":"Integr. Biol."},{"key":"10.1016\/j.biopha.2026.119626_bib19","doi-asserted-by":"crossref","unstructured":"Piersma B., Bank R.A., Boersema M. Signaling in Fibrosis: TGF-\u03b2, WNT, and YAP\/TAZ Converge. Front Med. 2:59. doi:10.3389\/fmed.2015.00059.","DOI":"10.3389\/fmed.2015.00059"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s44324-025-00063-4","article-title":"ECM formation and degradation during fibrosis, repair, and regeneration","volume":"3","author":"Mayorca-Guiliani","year":"2025","journal-title":"npj Metab. Health Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119626_bib22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrm3902","article-title":"Extracellular matrix assembly: a multiscale deconstruction","volume":"15","author":"Mouw","year":"2014","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119626_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib25","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41598-021-81591-z","article-title":"Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses","volume":"11","author":"Park","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119626_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.chest.2019.10.032","article-title":"Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis","volume":"157","author":"Sheng","year":"2020","journal-title":"CHEST"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2019.11.027","article-title":"Progressive Pulmonary Fibrosis Is Caused by Elevated Mechanical Tension on Alveolar Stem Cells","volume":"180","author":"Wu","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2026.119626_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.5858\/arpa.2011-0511-OA","article-title":"Idiopathic Pulmonary Fibrosis May Be a Disease of Recurrent, Tractional Injury to the Periphery of the Aging Lung: A Unifying Hypothesis Regarding Etiology and Pathogenesis","volume":"136","author":"Leslie","year":"2012","journal-title":"Arch. Pathol. & Lab. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib29","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1038\/s41467-018-07768-9","article-title":"Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice","volume":"9","author":"Hancock","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.202203-0622LE","article-title":"Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry","volume":"206","author":"Zhang","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119626_bib31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1164\/rccm.201910-1958OC","article-title":"Genome-Wide Association Study: Functional Variant rs2076295 Regulates Desmoplakin Expression in Airway Epithelial Cells","volume":"202","author":"Hao","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119626_bib32","doi-asserted-by":"crossref","unstructured":"Li X., Feng C., Peng S. Epigenetics alternation in lung fibrosis and lung cancer. Front Cell Dev Biol. 10:1060201. doi:10.3389\/fcell.2022.1060201.","DOI":"10.3389\/fcell.2022.1060201"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12931-024-02878-z","article-title":"Current state of signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis","volume":"25","author":"Zhou","year":"2024","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2026.119626_bib34","doi-asserted-by":"crossref","unstructured":"Liu H., Zhou D., Ou Y., Chen S., Long Y., Yuan T., et al. Multiple signaling pathways in the frontiers of lung cancer progression. Front Immunol. 16:1593793. doi:10.3389\/fimmu.2025.1593793.","DOI":"10.3389\/fimmu.2025.1593793"},{"issue":"12","key":"10.1016\/j.biopha.2026.119626_bib35","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","article-title":"Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis","volume":"192","author":"Xie","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/dvdy.24596","article-title":"Prospects for new lung cancer treatments that target EMT signaling","volume":"247","author":"Otsuki","year":"2018","journal-title":"Dev. Dyn."},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","article-title":"Revealing the Pathogenic and Aging-related Mechanisms of the Enigmatic Idiopathic Pulmonary Fibrosis. An Integral Model","volume":"189","author":"Selman","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119626_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102315","article-title":"Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions","volume":"97","author":"Jha","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: A strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03baB in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell. & Mol. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib42","article-title":"The JAK\/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications","volume":"5","author":"Liao","year":"2026","journal-title":"MedComm Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib44","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119626_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130037","article-title":"YAP induces FAK phosphorylation to inhibit gastric cancer cell proliferation via upregulation of HMGB1","volume":"262","author":"Jiang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119626_bib46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/21541248.2017.1413496","article-title":"Acute compressive stress activates RHO\/ROCK-mediated cellular processes","volume":"11","author":"Boyle","year":"2020","journal-title":"Small GTPases"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/gutjnl-2019-319748","article-title":"YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition","volume":"70","author":"Ajani","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. & Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ncb3478","article-title":"A mechanically active heterotypic E-cadherin\/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion","volume":"19","author":"Labernadie","year":"2017","journal-title":"Nat. Cell. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119626_bib50","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1083\/jcb.201702033","article-title":"Cancer-associated fibroblasts lead tumor invasion through integrin-\u03b23\u2013dependent fibronectin assembly","volume":"216","author":"Attieh","year":"2017","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119626_bib51","article-title":"Abundant intratumoral fibrosis prevents lymphocyte infiltration into peritoneal metastases of colorectal cancer","volume":"16","author":"Wang","year":"2021"},{"issue":"16","key":"10.1016\/j.biopha.2026.119626_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163881","article-title":"Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma","volume":"14","author":"Heger","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/imr.12990","article-title":"A bird\u2019s eye view of fibroblast heterogeneity: A pan-disease, pan-cancer perspective","volume":"302","author":"Pradhan","year":"2021","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib55","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","article-title":"Cancer-associated fibroblasts in the single-cell era","volume":"3","author":"Lavie","year":"2022","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib56","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","article-title":"Cancer-associated fibroblast classification in single-cell and spatial proteomics data","volume":"14","author":"Cords","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib57","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib58","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1038\/s41467-024-53233-1","article-title":"Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-Induced JAK\/STAT Signaling Is Antagonized by TGF\u03b2 to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.biopha.2026.119626_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4082","article-title":"Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression","volume":"22","author":"Laklai","year":"2016","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib61","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/ijms20071723","article-title":"The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma","volume":"20","author":"Baglieri","year":"2019","journal-title":"IJMS"},{"key":"10.1016\/j.biopha.2026.119626_bib62","doi-asserted-by":"crossref","unstructured":"Lee S.A., Cho G.J., Kim D., Kim D.H. Biophysical interplay between extracellular matrix remodeling and hypoxia signaling in regulating cancer metastasis. Front Cell Dev Biol. 12:1335636. doi:10.3389\/fcell.2024.1335636.","DOI":"10.3389\/fcell.2024.1335636"},{"issue":"9","key":"10.1016\/j.biopha.2026.119626_bib63","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.it.2024.07.009","article-title":"The extracellular matrix in solid tumor immunotherapy","volume":"45","author":"Cho","year":"2024","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082354","article-title":"Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities","volume":"15","author":"Myo Min","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tranon.2018.10.003","article-title":"Subcutaneous Inoculation of 3D Pancreatic Cancer Spheroids Results in Development of Reproducible Stroma-Rich Tumors","volume":"12","author":"Durymanov","year":"2019","journal-title":"Transl. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119626_bib66","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/modpathol.2015.97","article-title":"Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis","volume":"28","author":"Drifka","year":"2015","journal-title":"Mod. Pathol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119626_bib67","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.biopha.2026.119626_bib68","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1158\/1078-0432.CCR-13-1637","article-title":"Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy","volume":"19","author":"Smith","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119626_bib69","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119626_bib70","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.celrep.2016.04.019","article-title":"Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met\/FRA1\/HEY1 Signaling","volume":"15","author":"Lau","year":"2016","journal-title":"Cell. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib71","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2015-309655","article-title":"A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib72","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/curroncol30010016","article-title":"Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved","volume":"30","author":"Li","year":"2022","journal-title":"Curr. Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119626_bib73","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib74","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"10492","key":"10.1016\/j.biopha.2026.119626_bib75","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib76","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","article-title":"Immunosurveillance of the Liver by Intravascular Effector CD8+ T Cells","volume":"161","author":"Guidotti","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO","volume":"318","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1369\/00221554211056853","article-title":"Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity","volume":"70","author":"Aoki","year":"2022","journal-title":"J. Histochem. Cytochem."},{"issue":"11","key":"10.1016\/j.biopha.2026.119626_bib79","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/ijc.25920","article-title":"Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice","volume":"129","author":"Zhao","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib80","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3892\/ijo.2012.1497","article-title":"The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma","volume":"41","author":"Zhao","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib81","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1039\/c5ib00040h","article-title":"Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration","volume":"7","author":"Acerbi","year":"2015","journal-title":"Integr. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib82","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10549-012-2196-0","article-title":"Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production","volume":"135","author":"Shi","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.biopha.2026.119626_bib83","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","article-title":"Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population","volume":"47","author":"Korkaya","year":"2012","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib84","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-018-0818-9","article-title":"miR-190 suppresses breast cancer metastasis by regulation of TGF-\u03b2-induced epithelial\u2013mesenchymal transition","volume":"17","author":"Yu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib85","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13046-021-02070-x","article-title":"PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models","volume":"40","author":"Morosi","year":"2021","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"27","key":"10.1016\/j.biopha.2026.119626_bib86","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.biopha.2026.119626_bib87","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase\u2013like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib88","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/carcin\/bgp178","article-title":"Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src\/FAK pathway","volume":"30","author":"Peng","year":"2009","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib89","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0024","article-title":"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma","volume":"22","author":"Benson","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib90","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2016-0479","article-title":"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma","volume":"22","author":"Hecht","year":"2017","journal-title":"Oncologist"},{"issue":"30","key":"10.1016\/j.biopha.2026.119626_bib91","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1073\/pnas.1300415110","article-title":"CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer","volume":"110","author":"Neesse","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4_","key":"10.1016\/j.biopha.2026.119626_bib92","article-title":"LAPIS: Randomized phase 3 trial of chemotherapy (CTX) with and without pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC)","volume":"43","author":"Picozzi","year":"2025","journal-title":"JCO"},{"issue":"4_","key":"10.1016\/j.biopha.2026.119626_bib93","article-title":"Pamrevlumab plus nab-paclitaxel\/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial","volume":"43","author":"Picozzi","year":"2025","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib94","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119626_bib95","doi-asserted-by":"crossref","unstructured":"Zhao Q., He X., Qin X., Liu Y., Jiang H., Wang J., et al. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer. Front Immunol. 13:938439. doi:10.3389\/fimmu.2022.938439.","DOI":"10.3389\/fimmu.2022.938439"},{"issue":"13","key":"10.1016\/j.biopha.2026.119626_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35945","article-title":"Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study)","volume":"131","author":"Ramaswamy","year":"2025","journal-title":"Cancer"},{"issue":"5933","key":"10.1016\/j.biopha.2026.119626_bib97","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib98","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-20-3715","article-title":"Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer","volume":"27","author":"Steele","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","article-title":"A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma","volume":"45","author":"Ko","year":"2016","journal-title":"Pancreas"},{"issue":"36","key":"10.1016\/j.biopha.2026.119626_bib100","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized Phase Ib\/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib101","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/path.5320","article-title":"The integrin \u03b1v\u03b26 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy","volume":"249","author":"Reader","year":"2019","journal-title":"J. Pathol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju169","article-title":"Therapeutic Targeting of Integrin \u03b1v\u03b26 in Breast Cancer","volume":"106","author":"Moore","year":"2014","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib103","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdu474","article-title":"Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I\/II POSEIDON trial","volume":"26","author":"\u00c9lez","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mc.23273","article-title":"Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K\/AKT axis and downstream molecular network","volume":"60","author":"Zhang","year":"2021","journal-title":"Mol. Carcinog."},{"issue":"25","key":"10.1016\/j.biopha.2026.119626_bib105","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and Safety of Avutometinib \u00b1 Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.biopha.2026.119626_bib106","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1158\/0008-5472.CAN-13-0062","article-title":"Docetaxel Conjugate Nanoparticles That Target \u03b1-Smooth Muscle Actin\u2013Expressing Stromal Cells Suppress Breast Cancer Metastasis","volume":"73","author":"Murakami","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119626_bib107","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell."},{"issue":"5","key":"10.1016\/j.biopha.2026.119626_bib108","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-17-2033","article-title":"Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice","volume":"24","author":"Duperret","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.biopha.2026.119626_bib110","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-20-4001","article-title":"Fibroblast Activation Protein \u03b1-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity","volume":"27","author":"Sum","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib111","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","article-title":"Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model","volume":"49","author":"Liu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib112","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119626_bib113","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1053\/j.gastro.2011.06.047","article-title":"Retinoic Acid\u2013Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt\u2013\u03b2-Catenin Signaling to Slow Tumor Progression","volume":"141","author":"Froeling","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib114","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1038\/s41467-020-18636-w","article-title":"Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer","volume":"11","author":"Kocher","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib116","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1471-2407-13-294","article-title":"Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivomouse colon cancer model","volume":"13","author":"Milczarek","year":"2013","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2026.119626_bib117","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4161\/cbt.24350","article-title":"Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer","volume":"14","author":"Lawrence","year":"2013","journal-title":"Cancer Biol. & Ther."},{"issue":"50","key":"10.1016\/j.biopha.2026.119626_bib118","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"13","key":"10.1016\/j.biopha.2026.119626_bib119","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","article-title":"Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer","volume":"25","author":"Seo","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119626_bib120","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2326-6066.CIR-16-0303","article-title":"Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade","volume":"5","author":"Zboralski","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"18","key":"10.1016\/j.biopha.2026.119626_bib121","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT\/KEYNOTE-202 Trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib122","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.biopha.2026.119626_bib123","article-title":"Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma","volume":"5","author":"Grisendi","year":"2024","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.biopha.2026.119626_bib124","article-title":"Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous miR-302a","volume":"2019","author":"Li","year":"2019","journal-title":"Quesenberry PJ Quesenberry PJ Ed. Stem Cells Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13046-025-03336-4","article-title":"Innovative dual-gene delivery platform using miR-124 and PD-1 via umbilical cord mesenchymal stem cells and exosome for glioblastoma therapy","volume":"44","author":"Yueh","year":"2025","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.biopha.2026.119626_bib126","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1158\/1078-0432.CCR-17-3284","article-title":"Parallel accumulation of tumor hyaluronan, collagen, and other drivers of tumor progression","volume":"24","author":"Li","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119626_bib127","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","article-title":"Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer","volume":"22","author":"Hingorani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119626_bib128","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/0008-5472.CAN-12-2233","article-title":"LOX-Mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis","volume":"73","author":"Cox","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cyto.2012.09.013","article-title":"Connective tissue growth factor is a positive regulator of epithelial\u2013mesenchymal transition and promotes the adhesion with gastric cancer cells in human peritoneal mesothelial cells","volume":"61","author":"Jiang","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2026.119626_bib130","doi-asserted-by":"crossref","first-page":"i8","DOI":"10.1093\/annonc\/mdz029.015","article-title":"Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib131","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ijc.28972","article-title":"Deregulated expression of connective tissue growth factor (CTGF\/CCN2) is linked to poor outcome in human cancer","volume":"137","author":"Wells","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib132","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12916-022-02605-9","article-title":"Bifunctional anti-PD-L1\/TGF-\u03b2RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib133","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005267","article-title":"Phase 1 first-in-human study of dalutrafusp alfa, an anti\u2013CD73-TGF-\u03b2-trap bifunctional antibody, in patients with advanced solid tumors","volume":"11","author":"Tolcher","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib135","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib136","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell."},{"issue":"16_","key":"10.1016\/j.biopha.2026.119626_bib137","article-title":"Phase I study of ProAgio, an \u03b1v\u03b23 integrin cytotoxin, in patients with previously treated advanced pancreatic cancer and other solid tumors","volume":"42","author":"Skorupan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119626_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031726","article-title":"FAK in Cancer: From Mechanisms to Therapeutic Strategies","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119626_bib139","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","article-title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"33","author":"Jones","year":"2015","journal-title":"Investig. New. Drugs"},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib140","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND\u2014A Double-Blind, Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.biopha.2026.119626_bib141","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119626_bib142","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-16-2051","article-title":"FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma","volume":"23","author":"Casey","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.biopha.2026.119626_bib143","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1158\/1078-0432.CCR-21-2103","article-title":"Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer","volume":"27","author":"Vathiotis","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s11658-022-00351-7","article-title":"Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer","volume":"27","author":"Muchli\u0144ska","year":"2022","journal-title":"Cell. & Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib145","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1186\/s12885-020-07541-6","article-title":"High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer","volume":"20","author":"Li","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119626_bib146","doi-asserted-by":"crossref","unstructured":"Tong Y., Zhao Z., Zhang J., Wang W., Zhu Y. High expressions of CD10, FAP and GPR77 in CAFs are associated with chemoresistance and worse prognosis in gastric cancer. Front Oncol. 12:984817. doi:10.3389\/fonc.2022.984817.","DOI":"10.3389\/fonc.2022.984817"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib147","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"mAbs"},{"issue":"18","key":"10.1016\/j.biopha.2026.119626_bib148","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.3390\/cancers13184720","article-title":"The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis","volume":"13","author":"Asif","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119626_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101809","article-title":"CXCL12\/CXCR4: An amazing challenge and opportunity in the fight against fibrosis","volume":"83","author":"Wu","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119626_bib150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biopha.2026.119626_bib151","doi-asserted-by":"crossref","unstructured":"Golinelli G., Mastrolia I., Aramini B., Masciale V., Pinelli M., Pacchioni L., et al. Arming Mesenchymal Stromal\/Stem Cells Against Cancer: Has the Time Come? Front Pharmacol. 11:529921. doi:10.3389\/fphar.2020.529921.","DOI":"10.3389\/fphar.2020.529921"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28432","article-title":"Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells","volume":"64","author":"Oh","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib153","article-title":"TRAIL-Dependent Resolution of Pulmonary Fibrosis","volume":"2018","author":"Habiel","year":"2018","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101240","article-title":"Anti-GD2 CAR MSCs against metastatic Ewing\u2019s sarcoma","volume":"15","author":"Golinelli","year":"2022","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib155","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41598-018-37433-6","article-title":"Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer","volume":"9","author":"Spano","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119626_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051723","article-title":"Regulatory Mechanism of MicroRNA Expression in Cancer","volume":"21","author":"Ali Syeda","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119626_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","volume":"182","author":"Kara","year":"2022","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib158","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The safety of MSC therapy over the past 15 years: a meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell. Res. & Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib159","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12013-025-01895-z","article-title":"Mesenchymal Stem Cell-Based Therapies: Challenges and Enhancement Strategies","volume":"84","author":"Wong","year":"2025","journal-title":"Cell. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-025-02313-9","article-title":"Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies","volume":"10","author":"Han","year":"2025","journal-title":"Sig Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2026.119626_bib161","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s43018-023-00614-y","article-title":"A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer","volume":"4","author":"Chitty","year":"2023","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119626_bib162","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119626_bib163","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67904-8","article-title":"Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer","volume":"10","author":"Fujiwara","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/15384047.2022.2035629","article-title":"The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-\u03b2","volume":"23","author":"Wang","year":"2022","journal-title":"Cancer Biol. & Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073631","article-title":"Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin","volume":"23","author":"Branco","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"16_","key":"10.1016\/j.biopha.2026.119626_bib167","article-title":"Role of pirfenidone in the primary prophylaxis of lung cancer in idiopathic pulmonary fibrosis patients: A systematic review and meta-analysis","volume":"43","author":"Khan","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.biopha.2026.119626_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104481","article-title":"Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability","volume":"90","author":"Nambiar","year":"2023","journal-title":"eBioMedicine"},{"issue":"12","key":"10.1016\/j.biopha.2026.119626_bib169","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41416-018-0287-3","article-title":"Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells","volume":"119","author":"Tian","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.biopha.2026.119626_bib170","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1080\/14786419.2017.1385015","article-title":"Interactions of quercetin with receptor tyrosine kinases associated with human lung carcinoma","volume":"32","author":"Baby","year":"2018","journal-title":"Nat. Product. Res."},{"key":"10.1016\/j.biopha.2026.119626_bib171","article-title":"Nerandomilast, a PDE4B inhibitor, alleviates silica-induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF-\u03b2\/Smad signalling","author":"Wang","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119626_bib172","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in Patients with Progressive Pulmonary Fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib173","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/s41598-022-07044-3","article-title":"PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and \u03b2-catenin signaling pathways","volume":"12","author":"Guo","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119626_bib174","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-023-02551-x","article-title":"Expression of PD-1\/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis","volume":"24","author":"Karampitsakos","year":"2023","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2026.119626_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108504","article-title":"Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K\/Akt\/mTOR pathway","volume":"104","author":"Lu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119626_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112768","article-title":"PD-1\/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis","volume":"148","author":"Zhao","year":"2022","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.biopha.2026.119626_bib177","article-title":"Increased Expression of Epidermal Growth Factor Receptor (EGF-R) in Patients with Different Forms of Lung Fibrosis","volume":"2013","author":"Tzouvelekis","year":"2013","journal-title":"Ono S Ono S Ed. BioMed. Res. Int."},{"issue":"6","key":"10.1016\/j.biopha.2026.119626_bib178","doi-asserted-by":"crossref","first-page":"L1025","DOI":"10.1152\/ajplung.00526.2018","article-title":"Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib","volume":"316","author":"Epstein Shochet","year":"2019","journal-title":"Am. J. Physiol. -Lung Cell. Mol. Physiol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119626_bib179","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1096\/fj.12-224907","article-title":"Profibrotic TGF\u03b2 responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases","volume":"27","author":"Andrianifahanana","year":"2013","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.biopha.2026.119626_bib180","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1111\/cas.14488","article-title":"Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis","volume":"111","author":"Otsubo","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119626_bib181","article-title":"Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease","volume":"83","author":"H\u00e9luain","year":"2023","journal-title":"Respir. Med. Res."},{"key":"10.1016\/j.biopha.2026.119626_bib182","doi-asserted-by":"crossref","unstructured":"Duan K., Zhou H., Xu W., Yang L., Fan D., Zhang Z., et al. Evaluation of Tumor Fibrosis in Pancreatic Ductal Adenocarcinoma by 2-D Shear Wave Elastography: A Pilot Study. Ultrasound in Medicine and Biology. doi:10.1016\/j.ultrasmedbio.2023.06.003.","DOI":"10.1016\/j.ultrasmedbio.2023.06.003"},{"key":"10.1016\/j.biopha.2026.119626_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115146","article-title":"Novel bioprinted 3D model to human fibrosis investigation","volume":"165","author":"Petrachi","year":"2023","journal-title":"Biomed. & Pharmacother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:42:24Z","timestamp":1787438544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":183,"alternative-id":["S0753332226006621"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119626","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated and non-neoplastic fibrosis: Comparative mechanisms and emerging antifibrotic strategies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119626"}}